Certara has acquired Applied BioMath, a provider of model-informed drug discovery and development support to help accelerate and de-risk therapeutic research and development. Certara and Applied BioMath are the life sciences industry’s largest team of experts in quantitative systems pharmacology – QSP -, a method of biosimulation used across the development lifecycle to predict endpoints, biomarkers and the most effective dosing regimen. QSP combines computational modeling and experimental data to examine the relationships between a drug, the biological system, and the disease process. The resulting insights help scientists answer critical questions about novel therapies required for development progression including which patient populations are most likely to respond.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CERT:
- Certara initiated with a Neutral at UBS
- Certara initiated with neutral view at KeyBanc, here’s why
- Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
- Certara backs FY23 adjusted EPS view 44c-48c, consensus 45c
- Certara reports Q3 adjusted EPS 11c, consensus 11c